Send this resource to your team or professional network.
Evidence checked: September 15, 2026. Tirzepatide vs eloralintide vs mazdutide is a study comparison. No trial has tested all three against each other. Researchers studied each one in a different group of people. This guide keeps those results separate so the numbers stay clear.
Tirzepatide has the largest and longest published trial of the three. Eloralintide reached about 20% average weight loss in a smaller Phase 2 trial. Mazdutide reached 14.01% in a Phase 3 trial in China. These results come from different doses, people, and study lengths. A bigger number in one trial does not prove that one drug is stronger.
New to these terms? Read Are Ozempic, Mounjaro and Wegovy peptides? For a wider three-drug view, see our semaglutide vs tirzepatide vs retatrutide comparison.
Tirzepatide vs Eloralintide vs Mazdutide: Study Results
| Compound | Main study | People | Time | Best average result |
|---|---|---|---|---|
| Tirzepatide | SURMOUNT-1, Phase 3 | 2,539 adults | 72 weeks | 20.9% weight loss with 15 mg |
| Eloralintide | Phase 2 trial | 263 adults | 48 weeks | About 20% with 9 mg or 6-to-9 mg |
| Mazdutide | GLORY-1, Phase 3 | 610 adults | 48 weeks | 14.01% with 6 mg |
How to read this table: These were separate trials. The studies used different people, doses, and time points. Use the table to compare the evidence. Do not use it as a direct rank.
Tirzepatide vs Eloralintide vs Mazdutide: Quick Comparison
| Question | Tirzepatide | Eloralintide | Mazdutide |
|---|---|---|---|
| Main target | GIP and GLP-1 | Amylin receptor | GLP-1 and glucagon |
| Study stage | Large Phase 3 trial | Phase 2 paper; Phase 3 trial now listed in Canada | Phase 3 trial in China |
| Canada status | Marketed as Mounjaro and Zepbound | Canadian Phase 3 trial approved; not a marketed drug | Not a marketed Canadian drug |
| Simple takeaway | Most proven | Promising, but newer | Good Phase 3 data from China |
Frequently Asked Questions
This tirzepatide vs eloralintide vs mazdutide FAQ answers common research questions.
Which had the most weight loss in trials?
Tirzepatide has the best proof today. Its main trial had 2,539 adults and ran for 72 weeks. The 15 mg group lost 20.9% of body weight on average.
Eloralintide reached about 20% in a smaller 48-week Phase 2 trial. It looks strong, but it still needs Phase 3 proof. Mazdutide reached 14.01% at 48 weeks in its 6 mg Phase 3 group.
Is eloralintide stronger than tirzepatide?
We cannot say that yet. The early numbers look close. Tirzepatide reached 20.9% at 72 weeks in Phase 3. Eloralintide reached about 20% at 48 weeks in Phase 2. The eloralintide trial had 263 people. The tirzepatide trial had 2,539 people. Eloralintide looks promising. Tirzepatide has more proof.
Is mazdutide stronger than tirzepatide?
Published trials do not show that. Mazdutide 6 mg led to 14.01% weight loss at 48 weeks. Tirzepatide 15 mg led to 20.9% at 72 weeks. The studies used different people, so this was not a direct test. Tirzepatide has the stronger weight-loss record today.
How do tirzepatide, eloralintide, and mazdutide work?
| Compound | Signals it turns on | Simple meaning |
|---|---|---|
| Tirzepatide | GIP and GLP-1 | Helps lower hunger and improve blood sugar |
| Eloralintide | Amylin pathway | Uses a fullness signal that helps the brain feel fed |
| Mazdutide | GLP-1 and glucagon | Targets hunger and energy use |
All three were given once a week in the main studies.
Which one is best for appetite control?
All three lowered weight. This means each one helped people eat less, use energy in a better way, or both. In SURMOUNT-1, 91% of people on tirzepatide 15 mg lost at least 5% of body weight. Eloralintide also had strong results. Its 9 mg group lost about 20% at 48 weeks. With mazdutide 6 mg, 82.0% of people lost at least 5% by week 32.
Which one was easier on the stomach?
| Compound | What the trial reported |
|---|---|
| Tirzepatide | Stomach side effects were most common. Most were mild or moderate. They happened most during dose increases. |
| Eloralintide | Nausea reached 64% in one 6 mg group. Placebo was 14%. Fatigue reached 43% in the 9 mg group and 46% in the 6-to-9 mg group. |
| Mazdutide | Stomach side effects were most common and often came during dose increases. |
Side effects often rose as the dose rose. This does not prove that one compound is easier for every person.
How soon did the studies show weight changes?
The main results did not come from week 1. Tirzepatide reported its main result at 72 weeks. Eloralintide reported at 48 weeks. Mazdutide reported at 32 and 48 weeks. Appetite can change before the scale changes a lot. The large study results took months.
Can fast weight loss include muscle loss?
Yes. Fast weight loss can include some lean mass loss. The tirzepatide trial showed up to 20.9% body weight loss. Changes that large make protein and strength work important. Many clinicians use two or more strength sessions each week as a simple target. Ask a clinician about protein, strength work, and body scans.
What happens after tirzepatide, eloralintide, or mazdutide is stopped?
Weight often comes back after a person stops an obesity medicine. In the SURMOUNT-4 study, people who stayed on tirzepatide kept losing weight. People who switched to placebo gained weight over the next 52 weeks. We do not have the same stop-and-follow data for eloralintide or mazdutide.
Are tirzepatide, eloralintide, and mazdutide approved in Canada?
Tirzepatide is marketed in Canada as Mounjaro. Zepbound also appears as a marketed product in Health Canada’s drug portal. Eloralintide has a Canadian Phase 3 trial. Health Canada approved that trial on February 24, 2026. A trial approval does not mean the drug is sold as a medicine. Mazdutide has Phase 3 data from China. It is not a marketed Canadian drug.
For more Canadian context, read about tirzepatide and sleep apnea in Canada.
Which one has the strongest research paper?
Tirzepatide has the strongest full package. SURMOUNT-1 was a large Phase 3 trial with 2,539 adults over 72 weeks. Mazdutide also has a strong Phase 3 paper. It studied 610 adults in China over 48 weeks. Eloralintide has a good Phase 2 paper in The Lancet. It studied 263 adults over 48 weeks. Large Phase 3 trials can give clearer answers than smaller Phase 2 trials.
Which compound should researchers watch next?
Eloralintide is one to watch. Its 48-week Phase 2 result came close to the tirzepatide result through a different pathway. A Canadian Phase 3 trial is now recruiting.
Mazdutide also matters. Its glucagon pathway may help researchers study liver fat and metabolic health. Its best published obesity result in this guide is 14.01% at 48 weeks. Tirzepatide stays the main benchmark until newer Phase 3 data gives a stronger answer.
Researchers comparing newer multi-receptor compounds can also read our tirzepatide vs retatrutide guide and our review of retatrutide clinical trials.
The sources below support the tirzepatide vs eloralintide vs mazdutide trial data in this guide.
Sources
- Tirzepatide: Jastreboff et al., SURMOUNT-1, New England Journal of Medicine, 2022. PMID 35658024. Read the PubMed record.
- Tirzepatide stopping data: Aronne et al., SURMOUNT-4, JAMA, 2024. PMID 38078870. Read the PubMed record.
- Eloralintide: Billings et al., The Lancet, 2025. PMID 41207310. Read the PubMed record.
- Eloralintide Canadian Phase 3 trial: Health Canada Clinical Trials Search Portal, control number 305917. View the trial listing.
- Mazdutide: Ji et al., GLORY-1, New England Journal of Medicine, 2025. PMID 40421736. Read the PubMed record.
- Zepbound Canada listing: Health Canada Drug and Health Products Portal.
- Mounjaro Canada listing: Health Canada Drug and Health Products Portal.
Use these guides to place tirzepatide vs eloralintide vs mazdutide in the wider peptide research field.
Related Research Guides
- Tirzepatide vs Retatrutide: A Canadian Research Comparison
- Semaglutide vs Tirzepatide vs Retatrutide
- Retatrutide Research and Clinical Trials
- Are Ozempic, Mounjaro and Wegovy Peptides?
